Physician profile
Anil Mathur
NPI 1811061104
$2,230.27
in general payments reported to CMS, 2019-2025
10 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $244 · 2021: $160 · 2022: $553 · 2023: $492 · 2024: $125 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $664.80 | 2019-2023 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $471.66 | 2020-2023 | Eliquis |
| Novo Nordisk INC | $374.97 | 2024-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $124.99 | 2022 | |
| Intuitive Surgical, INC. | $124.99 | 2025 | |
| Merck Sharp & Dohme LLC | $100.00 | 2023 | Verquvo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $61.90 | 2022 | |
| Pfizer INC. | $44.08 | 2020-2021 | |
| Amgen INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.